» Articles » PMID: 26134832

Modeling the Physiological Factors Affecting Glucose Sensor Function in Vivo

Overview
Specialty Endocrinology
Date 2015 Jul 3
PMID 26134832
Citations 9
Authors
Affiliations
Soon will be listed here.
Abstract

For implantable sensors to become a more viable option for continuous glucose monitoring strategies, they must be able to persist in vivo for periods longer than the 3- to 7-day window that is the current industry standard. Recent studies have attributed such limited performance to tissue reactions resulting from implantation. While in vivo biocompatibility studies have provided much in the way of understanding histology surrounding an implanted sensor, little is known about how each constituent of the foreign body response affects sensor function. Due to the ordered composition and geometry of implant-associated tissue reactions, their effects on sensor function may be computationally modeled and analyzed in a way that would be prohibitive using in vivo studies. This review both explains how physiologically accurate computational models of implant-associated tissue reaction can be designed and shows how they have been utilized thus far. Going forward, these in silico models of implanted sensor behavior may soon complement in vivo studies to provide valuable information for improved sensor designs.

Citing Articles

Impact of Bindarit, a CCL2 Chemokine Synthesis Inhibitor, on Macrophage-Based Biofouling and Continuous Glucose Monitoring .

Sharafieh R, Qiao Y, Godlewski I, Czajkowski C, Wu R, Hargis G Biosens Bioelectron X. 2024; 19.

PMID: 39703931 PMC: 11654743. DOI: 10.1016/j.biosx.2024.100511.


Insertable Biomaterial-Based Multianalyte Barcode Sensor toward Continuous Monitoring of Glucose and Oxygen.

Pradhan R, Chimene D, Ko B, Goncharov A, Ozcan A, McShane M ACS Sens. 2024; 9(11):6060-6070.

PMID: 39494514 PMC: 11590103. DOI: 10.1021/acssensors.4c01926.


A thermal activated and differential self-calibrated flexible epidermal biomicrofluidic device for wearable accurate blood glucose monitoring.

Pu Z, Zhang X, Yu H, Tu J, Chen H, Liu Y Sci Adv. 2021; 7(5).

PMID: 33571117 PMC: 7840141. DOI: 10.1126/sciadv.abd0199.


Continuous Glucose Monitoring Devices: Past, Present, and Future Focus on the History and Evolution of Technological Innovation.

Didyuk O, Econom N, Guardia A, Livingston K, Klueh U J Diabetes Sci Technol. 2020; 15(3):676-683.

PMID: 31931614 PMC: 8120065. DOI: 10.1177/1932296819899394.


Fibrotic Encapsulation Is the Dominant Source of Continuous Glucose Monitor Delays.

McClatchey P, McClain E, Williams I, Malabanan C, James F, Lord P Diabetes. 2019; 68(10):1892-1901.

PMID: 31399432 PMC: 6754243. DOI: 10.2337/db19-0229.


References
1.
Novak M, Yuan F, Reichert W . Modeling the relative impact of capsular tissue effects on implanted glucose sensor time lag and signal attenuation. Anal Bioanal Chem. 2010; 398(4):1695-705. PMC: 2966551. DOI: 10.1007/s00216-010-4097-6. View

2.
Luni C, Marth J, Doyle 3rd F . Computational modeling of glucose transport in pancreatic β-cells identifies metabolic thresholds and therapeutic targets in diabetes. PLoS One. 2013; 7(12):e53130. PMC: 3531366. DOI: 10.1371/journal.pone.0053130. View

3.
Parker R, Doyle 3rd F, Peppas N . The intravenous route to blood glucose control. IEEE Eng Med Biol Mag. 2001; 20(1):65-73. DOI: 10.1109/51.897829. View

4.
Parker R, Doyle 3rd F, Peppas N . A model-based algorithm for blood glucose control in type I diabetic patients. IEEE Trans Biomed Eng. 1999; 46(2):148-57. DOI: 10.1109/10.740877. View

5.
. Economic costs of diabetes in the U.S. In 2007. Diabetes Care. 2008; 31(3):596-615. DOI: 10.2337/dc08-9017. View